




PENDING

(IN201911011317)

## Lipidic nanocarriers embedded topical preparation of pde4 inhibitors



## NEED

More than 30% of topical treatments for psoriasis and eczema fail because drugs degrade or penetrate poorly through the skin's outer layer. Current systems lose up to 50% of active ingredients, reducing patient outcomes and prolonging healing.

## TECHNOLOGY OVERVIEW

This patent presents a lipidic nanocarrier system embedding PDE4 inhibitors, enhancing their permeation across the skin barrier. Using a hot emulsification method, it enables controlled, prolonged drug release with improved skin retention, supporting treatment of chronic skin inflammatory diseases without rapid drug loss.

## TECHNOLOGY KEY FEATURES

Particle size 50–400 nm, drug loading 0.05–5% w/w, lipid content 1–10% w/w, advanced hot emulsification technique, prolonged drug retention, multiple compatible therapeutic agents, improved skin permeation efficiency over existing topical solutions.

[Read more here](#)

## MARKET ANALYSIS

The global topical drug delivery market is expected to grow at a CAGR of 7.5%, reaching \$195 billion by 2033, driven by rising cases of chronic skin diseases and demand for non-invasive therapies. [Source: Market Research Future, 2024]

## Target Industries

Dermatology, Pharma, Advanced Cosmeceuticals, Chronic Disease Topical Therapeutics, Pharmaceutical formulation developers, nanotechnology delivery platform providers, topical product R&D units focusing on inflammatory skin conditions.

## AT A GLANCE

- SDG 3 (Good Health and Well-being), SDG 9 (Industry, Innovation, and Infrastructure), SDG 12 (Responsible Consumption and Production)

Technology is available for licensing/ co-development.

Reach out to Prof. Deepak Chitkara, Coordinator, BITS Technology Enabling Centre,

BITS Pilani Contact Details: [tec.bits@pilani.bits-pilani.ac.in](mailto:tec.bits@pilani.bits-pilani.ac.in), 91 1596-255913

